Bamco Inc. NY Makes New Investment in Cytokinetics, Incorporated $CYTK

Firm purchased 24,500 shares of the biopharmaceutical company's stock, valued at approximately $1.3 million.

Mar. 17, 2026 at 7:35am

Got story updates? Submit your updates here. ›

Bamco Inc. NY purchased a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK) during the 3rd quarter, according to the company's recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 24,500 shares of the biopharmaceutical company's stock, valued at approximately $1,347,000.

Why it matters

This investment by Bamco Inc. NY in Cytokinetics, a late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function, signals potential confidence in the company's pipeline and future growth prospects.

The details

Bamco Inc. NY purchased the new stake in Cytokinetics as part of its investment portfolio during the 3rd quarter. The 24,500 shares acquired are valued at approximately $1.3 million. Cytokinetics is a California-based company that applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance, with a focus on both cardiac and skeletal muscle targets.

  • Bamco Inc. NY purchased the new stake in Cytokinetics during the 3rd quarter.

The players

Bamco Inc. NY

An investment management firm that purchased a new stake in Cytokinetics, Incorporated.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function, headquartered in South San Francisco, California.

Got photos? Submit your photos here. ›

The takeaway

This investment by Bamco Inc. NY in Cytokinetics suggests that the investment firm sees potential in the biopharmaceutical company's pipeline and future growth prospects, as Cytokinetics continues to advance its novel muscle-modulating therapies through clinical development.